ForPatients

by Roche

Age-Related Macular Degeneration

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02698566 GX30020

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.

Genentech, Inc. Sponsor		Phase 3 Phase	
NCT02698566 GX30020 Trial Identifiers			
Eligibility Criteria:			
Gender All	Age >= 18 Years		Healthy Volunteers